| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/26/2002 | WO2002074768A1 Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) |
| 09/26/2002 | WO2002074767A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074765A1 Phenyl derivatives 3 |
| 09/26/2002 | WO2002074764A2 Piperazine derivatives and their use as 5-ht1b ligands |
| 09/26/2002 | WO2002074763A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | WO2002074761A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors |
| 09/26/2002 | WO2002074758A2 Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| 09/26/2002 | WO2002074754A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 09/26/2002 | WO2002074752A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074751A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074750A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074749A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074748A1 Metalloproteinase inhibitors |
| 09/26/2002 | WO2002074742A2 Cdk-inhibitory indirubin derivatives having an increased solubility |
| 09/26/2002 | WO2002074733A2 Tryptase-inhibitors |
| 09/26/2002 | WO2002074730A1 INHIBITORS OF INTEGRIN αvβ¿6? |
| 09/26/2002 | WO2002074726A2 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | WO2002074388A1 Bisarylamines as potassium channel openers |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002074326A2 Urocortin-iii and uses thereof |
| 09/26/2002 | WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 09/26/2002 | WO2002074318A1 Il-12 expression controlling agents |
| 09/26/2002 | WO2002074312A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | WO2002074297A1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| 09/26/2002 | WO2002074293A2 Methods for restoring cognitive function following systemic stress |
| 09/26/2002 | WO2002074292A2 Hormone replacement therapy |
| 09/26/2002 | WO2002074286A1 Transdermal patch for administering fentanyl |
| 09/26/2002 | WO2002074249A2 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | WO2002074243A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders |
| 09/26/2002 | WO2002074240A2 Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder |
| 09/26/2002 | WO2002074238A2 Water soluble and palatable complexes |
| 09/26/2002 | WO2002074230A2 A dna molecule encoding a variant paraoxonase and uses thereof |
| 09/26/2002 | WO2002074200A1 Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| 09/26/2002 | WO2002074056A2 Allosteric adenosine receptor modulators |
| 09/26/2002 | WO2002062999A8 Proteins and nucleic acids encoding same |
| 09/26/2002 | WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus |
| 09/26/2002 | WO2002044126A3 Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| 09/26/2002 | WO2002040487A3 Benzodiazepine derivatives as gaba a receptor modulators |
| 09/26/2002 | WO2002036116A3 Tripeptidyl peptidase inhibitors |
| 09/26/2002 | WO2002026996A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 09/26/2002 | WO2002024636A3 N-acylsulfonamide apoptosis promoters |
| 09/26/2002 | WO2002018334B1 Sodium channel modulators |
| 09/26/2002 | WO2002003975A3 Combinations of ssri and estrogenic agents |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001091756A3 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| 09/26/2002 | WO2001087343A3 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 09/26/2002 | WO2001085093A9 Compounds and methods for modulating cerebral amyloid angiopathy |
| 09/26/2002 | WO2001083775A3 Proteases |
| 09/26/2002 | WO2001080837A2 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 09/26/2002 | WO2001076568A3 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 09/26/2002 | WO2001073002A3 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 09/26/2002 | WO2001070969A3 Regulation of human latrophilin-like g protein-coupled receptor |
| 09/26/2002 | WO2001052847A8 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001019977A9 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 09/26/2002 | WO2001019823A9 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137938 Novel process |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137931 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 09/26/2002 | US20020137907 Novel compounds |
| 09/26/2002 | US20020137903 Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes |
| 09/26/2002 | US20020137892 An isolated peptide transmitter-like receptor polypeptide with specific amino acid sequence or variant which has immunomodulatory, neuromodulatory and endocrinomodulatory activity |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137763 (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione |
| 09/26/2002 | US20020137761 Treating tolerance or drug addiction; analgesics |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137750 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137742 Benzenesulfonamide compounds |
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137738 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 09/26/2002 | US20020137737 1-(3-methyl-1-(1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4 -benzodiazepin-3-ylcarbamoyl)-butyl)-cyclopent-3-enecarboxylic amide, for example; gamma-secretase inhibitors; Alzhemier's disease, Down's Syndrome |
| 09/26/2002 | US20020137736 Novel compounds |
| 09/26/2002 | US20020137721 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137669 Treatment of dyskinesia |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137155 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher Basidiomycetes mushroom |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137132 Genetic engineering; diagnosis of psychological disorders |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137095 Reelin protein CR-50 epitope region |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020137049 Pablo, a polypeptide that interacts with Bcl-xL, and uses related thereto |
| 09/26/2002 | US20020137028 Use of neuronal apoptosis inhibitor protein (naip) |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | US20020136718 Using antibody which catalyzes hydrolysis of beta-amyloid at a predetermined amide linkage |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2442717A1 Methods for restoring cognitive function following systemic stress |
| 09/26/2002 | CA2442268A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | CA2441740A1 Dopaminergic neuronal survival-promoting factors and uses thereof |
| 09/26/2002 | CA2441563A1 Allosteric adenosine receptor modulators |